Oral immunization with hepatitis B surface antigen expressed in transgenic plants

Qingxian Kong, Liz Richter, Yu Fang Yang, Charles J. Arntzen, Hugh Mason, Yasmin Thanavala

Research output: Contribution to journalArticle

267 Citations (Scopus)

Abstract

Oral immunogenicity of recombinant hepatitis B surface antigen (HBsAg) derived from yeast (purified product) or in transgenic potatoes (uncooked unprocessed sample) was compared. An oral adjuvant, cholera toxin, was used to increase immune responses. Transgenic plant material containing HBsAg was the superior means of both inducing a primary immune response and priming the mice to respond to a subsequent parenteral injection of HBsAg. Electron microscopy of transgenic plant samples revealed evidence that the HBsAg accumulated intracellularly; we conclude that natural bioencapsulation of the antigen may provide protection from degradation in the digestive tract until plant cell degradation occurs near an immune effector site in the gut. The correlate of protection from hepatitis B virus infection is serum antibody titers induced by vaccination; the protective level in humans is 10 milliunits/ml or greater. Mice fed HBsAg-transgenic potatoes produced HBsAg-specific serum antibodies that exceeded the protective level and, on parenteral boosting, generated a strong longlasting secondary antibody response. We have also shown the effectiveness of oral delivery by using a parenteral prime-oral boost immunization schedule. The demonstrated success of oral immunization for hepatitis B virus with an "edible vaccine" provides a strategy for contributing a means to achieve global immunization for hepatitis B prevention and eradication.

Original languageEnglish (US)
Pages (from-to)11539-11544
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume98
Issue number20
DOIs
StatePublished - Sep 25 2001

Fingerprint

Genetically Modified Plants
Hepatitis B Surface Antigens
Immunization
Solanum tuberosum
Hepatitis B virus
Edible Vaccines
Immunization Schedule
Antibodies
Cholera Toxin
Plant Cells
Virus Diseases
Hepatitis B
Serum
Antibody Formation
Gastrointestinal Tract
Electron Microscopy
Vaccination
Yeasts
Antigens
Injections

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Oral immunization with hepatitis B surface antigen expressed in transgenic plants. / Kong, Qingxian; Richter, Liz; Yang, Yu Fang; Arntzen, Charles J.; Mason, Hugh; Thanavala, Yasmin.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 98, No. 20, 25.09.2001, p. 11539-11544.

Research output: Contribution to journalArticle

Kong, Qingxian ; Richter, Liz ; Yang, Yu Fang ; Arntzen, Charles J. ; Mason, Hugh ; Thanavala, Yasmin. / Oral immunization with hepatitis B surface antigen expressed in transgenic plants. In: Proceedings of the National Academy of Sciences of the United States of America. 2001 ; Vol. 98, No. 20. pp. 11539-11544.
@article{9affe3afd1d9455dae6ed7dc51f2cc58,
title = "Oral immunization with hepatitis B surface antigen expressed in transgenic plants",
abstract = "Oral immunogenicity of recombinant hepatitis B surface antigen (HBsAg) derived from yeast (purified product) or in transgenic potatoes (uncooked unprocessed sample) was compared. An oral adjuvant, cholera toxin, was used to increase immune responses. Transgenic plant material containing HBsAg was the superior means of both inducing a primary immune response and priming the mice to respond to a subsequent parenteral injection of HBsAg. Electron microscopy of transgenic plant samples revealed evidence that the HBsAg accumulated intracellularly; we conclude that natural bioencapsulation of the antigen may provide protection from degradation in the digestive tract until plant cell degradation occurs near an immune effector site in the gut. The correlate of protection from hepatitis B virus infection is serum antibody titers induced by vaccination; the protective level in humans is 10 milliunits/ml or greater. Mice fed HBsAg-transgenic potatoes produced HBsAg-specific serum antibodies that exceeded the protective level and, on parenteral boosting, generated a strong longlasting secondary antibody response. We have also shown the effectiveness of oral delivery by using a parenteral prime-oral boost immunization schedule. The demonstrated success of oral immunization for hepatitis B virus with an {"}edible vaccine{"} provides a strategy for contributing a means to achieve global immunization for hepatitis B prevention and eradication.",
author = "Qingxian Kong and Liz Richter and Yang, {Yu Fang} and Arntzen, {Charles J.} and Hugh Mason and Yasmin Thanavala",
year = "2001",
month = "9",
day = "25",
doi = "10.1073/pnas.191617598",
language = "English (US)",
volume = "98",
pages = "11539--11544",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "20",

}

TY - JOUR

T1 - Oral immunization with hepatitis B surface antigen expressed in transgenic plants

AU - Kong, Qingxian

AU - Richter, Liz

AU - Yang, Yu Fang

AU - Arntzen, Charles J.

AU - Mason, Hugh

AU - Thanavala, Yasmin

PY - 2001/9/25

Y1 - 2001/9/25

N2 - Oral immunogenicity of recombinant hepatitis B surface antigen (HBsAg) derived from yeast (purified product) or in transgenic potatoes (uncooked unprocessed sample) was compared. An oral adjuvant, cholera toxin, was used to increase immune responses. Transgenic plant material containing HBsAg was the superior means of both inducing a primary immune response and priming the mice to respond to a subsequent parenteral injection of HBsAg. Electron microscopy of transgenic plant samples revealed evidence that the HBsAg accumulated intracellularly; we conclude that natural bioencapsulation of the antigen may provide protection from degradation in the digestive tract until plant cell degradation occurs near an immune effector site in the gut. The correlate of protection from hepatitis B virus infection is serum antibody titers induced by vaccination; the protective level in humans is 10 milliunits/ml or greater. Mice fed HBsAg-transgenic potatoes produced HBsAg-specific serum antibodies that exceeded the protective level and, on parenteral boosting, generated a strong longlasting secondary antibody response. We have also shown the effectiveness of oral delivery by using a parenteral prime-oral boost immunization schedule. The demonstrated success of oral immunization for hepatitis B virus with an "edible vaccine" provides a strategy for contributing a means to achieve global immunization for hepatitis B prevention and eradication.

AB - Oral immunogenicity of recombinant hepatitis B surface antigen (HBsAg) derived from yeast (purified product) or in transgenic potatoes (uncooked unprocessed sample) was compared. An oral adjuvant, cholera toxin, was used to increase immune responses. Transgenic plant material containing HBsAg was the superior means of both inducing a primary immune response and priming the mice to respond to a subsequent parenteral injection of HBsAg. Electron microscopy of transgenic plant samples revealed evidence that the HBsAg accumulated intracellularly; we conclude that natural bioencapsulation of the antigen may provide protection from degradation in the digestive tract until plant cell degradation occurs near an immune effector site in the gut. The correlate of protection from hepatitis B virus infection is serum antibody titers induced by vaccination; the protective level in humans is 10 milliunits/ml or greater. Mice fed HBsAg-transgenic potatoes produced HBsAg-specific serum antibodies that exceeded the protective level and, on parenteral boosting, generated a strong longlasting secondary antibody response. We have also shown the effectiveness of oral delivery by using a parenteral prime-oral boost immunization schedule. The demonstrated success of oral immunization for hepatitis B virus with an "edible vaccine" provides a strategy for contributing a means to achieve global immunization for hepatitis B prevention and eradication.

UR - http://www.scopus.com/inward/record.url?scp=0035949504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035949504&partnerID=8YFLogxK

U2 - 10.1073/pnas.191617598

DO - 10.1073/pnas.191617598

M3 - Article

VL - 98

SP - 11539

EP - 11544

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 20

ER -